Tong, H., Gao, S., Yang, W., Li, J., Yin, Q., Zhao, X., Yan, X., Tu, S., Li, F., Yang, H., Hu, R., Wang, S., Ma, L., Dong, Z., Lu, Q., Tian, W., Xiao, Z., Wang, J. (2025). Updated results of a phase 2 study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6577